Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679038 | 1.00 | DDAH1 (0.59) | DDAH1POLBGAANPSR1NPC1 | |
| SCHEMBL4562346 | 0.81 | DDAH1 (0.59) | DDAH1POLBGAANPC1RAB9A | |
| SCHEMBL4124111 | 0.81 | DDAH1 (0.65) | DDAH1POLBGAANPC1RAB9A | |
| SCHEMBL6756255 | 0.79 | GAA (0.57) | DDAH1POLBGAANPC1RAB9A | |
| SCHEMBL19651813 | 0.79 | DDAH1 (0.61) | DDAH1POLBGAANPC1RAB9A | |
| SCHEMBL10761755 | 0.79 | DDAH1 (0.61) | DDAH1POLBGAANPC1RAB9A | |
| SCHEMBL4619198 | 0.79 | DDAH1 (0.61) | DDAH1POLBGAANPC1RAB9A | |
| SCHEMBL10696188 | 0.79 | DDAH1 (0.66) | DDAH1POLBGAANPSR1NPC1 | |
| SCHEMBL230024 | 0.78 | GAA (0.78) | DDAH1POLBGAANPC1RAB9A | |
| SCHEMBL230157 | 0.78 | POLB (0.84) | DDAH1POLBGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166734-A1 | ANTI-GDF-15 ANTIBODIES | AVEO PHARMACEUTICALS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11957683-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11725047-B2 | Anti-GDF-15 antibodies | AVEO PHARMACEUTICALS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-105073133-B | anti-GDF 15 antibodies | AVEO制药公司 | 2021-04-20 | — | — | CN | disclosed |
| US-10975154-B2 | Binding proteins and methods of use thereof | NGM BIOPHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210101968-A1 | ANTI-GDF-15 ANTIBODIES | AVEO PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-3689370-A1 | ANTI-GDF15 ANTIBODIES | Aveo Pharmaceuticals Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10597444-B2 | Anti-GDF15 antibodies | AVEO PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-2934584-B1 | ANTI-GDF15 ANTIBODIES | AVEO PHARMACEUTICALS INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-2934584-A1 | ANTI-GDF15 ANTIBODIES | Aveo Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140193427-A1 | ANTI-GDF15 ANTIBODIES | AVEO PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014100689-A1 | ANTI-GDF15 ANTIBODIES | AVEO PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8563540-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440651-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-14 | — | — | US | disclosed |
| EP-2539337-A1 | PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| CN-102762565-A | Pyrido [3,2-d ] pyrimidine PI3 inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2012-10-31 | — | — | CN | disclosed |
| WO-2011101429-A1 | PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | DDAH1 1592/4885POLB 275/4885GAA 2117/4885 |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | DDAH1 4021/4885POLB 3123/4885GAA 172/4885 |
| US-11957683-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | DDAH1 4021/4885POLB 3123/4885GAA 172/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | DDAH1 1592/4885POLB 275/4885GAA 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.